1. Home
  2. RYAM vs DRUG Comparison

RYAM vs DRUG Comparison

Compare RYAM & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYAM
  • DRUG
  • Stock Information
  • Founded
  • RYAM 1926
  • DRUG 2019
  • Country
  • RYAM United States
  • DRUG United States
  • Employees
  • RYAM N/A
  • DRUG N/A
  • Industry
  • RYAM Paper
  • DRUG Pharmaceuticals and Biotechnology
  • Sector
  • RYAM Basic Materials
  • DRUG Health Care
  • Exchange
  • RYAM Nasdaq
  • DRUG Nasdaq
  • Market Cap
  • RYAM 271.1M
  • DRUG 233.2M
  • IPO Year
  • RYAM N/A
  • DRUG N/A
  • Fundamental
  • Price
  • RYAM $3.87
  • DRUG $27.31
  • Analyst Decision
  • RYAM Buy
  • DRUG Strong Buy
  • Analyst Count
  • RYAM 1
  • DRUG 6
  • Target Price
  • RYAM $6.00
  • DRUG $83.25
  • AVG Volume (30 Days)
  • RYAM 440.9K
  • DRUG 19.6K
  • Earning Date
  • RYAM 08-05-2025
  • DRUG 08-13-2025
  • Dividend Yield
  • RYAM N/A
  • DRUG N/A
  • EPS Growth
  • RYAM N/A
  • DRUG N/A
  • EPS
  • RYAM N/A
  • DRUG N/A
  • Revenue
  • RYAM $1,598,619,000.00
  • DRUG N/A
  • Revenue This Year
  • RYAM N/A
  • DRUG N/A
  • Revenue Next Year
  • RYAM $3.23
  • DRUG N/A
  • P/E Ratio
  • RYAM N/A
  • DRUG N/A
  • Revenue Growth
  • RYAM 2.20
  • DRUG N/A
  • 52 Week Low
  • RYAM $3.45
  • DRUG $0.93
  • 52 Week High
  • RYAM $10.28
  • DRUG $79.02
  • Technical
  • Relative Strength Index (RSI)
  • RYAM 43.38
  • DRUG 41.95
  • Support Level
  • RYAM $3.83
  • DRUG $27.69
  • Resistance Level
  • RYAM $3.99
  • DRUG $28.74
  • Average True Range (ATR)
  • RYAM 0.14
  • DRUG 1.29
  • MACD
  • RYAM 0.02
  • DRUG 0.14
  • Stochastic Oscillator
  • RYAM 30.39
  • DRUG 39.29

About RYAM Rayonier Advanced Materials Inc.

Rayonier Advanced Materials Inc is engaged in the production of cellulose specialties, a natural polymer used in the manufacturing of various specialty chemical products, including liquid crystal displays, filters, textiles and performance additives for pharmaceutical, food and other industrial applications. The company's products are used in a variety of applications, including cigarette filters, liquid crystal displays, paints, pharmaceuticals, and food. The company operates in the reportable segments of High Purity Cellulose, Paperboard, and High-Yield Pulp. The key revenue is derived from the High Purity Cellulose segment. Geographically, it derives a majority of its revenue from the United States.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: